Triple-Threat attack on rare, deadly blood cancer
NCT ID NCT05672173
Summary
This study is testing a new combination of three cancer drugs for patients with Richter's transformation, a rare and aggressive form of blood cancer that develops from chronic lymphocytic leukemia (CLL). The treatment combines a personalized cell therapy (made from the patient's own immune cells) with two other drugs that help the immune system fight cancer. The main goal is to see if this three-drug approach can completely eliminate detectable cancer in patients who have few other treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.